Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cardiovascular/Ischemia

Ischemia

36

Pipeline Programs↗

34

Active Trials↗

29

Companies Involved↗

Ischemia is a moderately active landscape with 36 programs across 29 companies. The most active players are Beijing Northland Biotech. Co., Ltd.. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

42/100

Mech. Concentration

18/100

Completion Rate

82/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Beijing Northland Biotech. Co., Ltd.

1 program

Pipeline

Programs by Phase

Preclinical25

Ambrisentan

Gilead

Platelet Rich Plasma

Zagazig University

Naloxone

Scienture

Morphine

Hikma Pharmaceuticals LLC

Simvastatin

Organon and Co

Phase 12

Epcs

Allife Medical Science and Technology Co., Ltd.

Ensure Surgery Immunonutrition Shake

Boston Medical Center

Phase 25

CELULAS TRONCO

UPECLIN HC FM Botucatu Unesp

Multigeneangio

MultiGene Vascular Systems Ltd.

TP03HN106

Talengen Institute of Life Sciences, Shenzhen, P.R. China.

Milrinone

Sanofi

Albumin

Laboratoire français de Fractionnement et de Biotechnologies

Phase 34

Metronidazole

DePuy Orthopaedics

Gentamicin

Schering-Plough

Recombinant Nonimmunogenic Staphylokinase

Supergene, LLC

Sovateltide

Pharmazz, Inc.

Approved

No programs

Analysis

Modality Breakdown

91%

Small molecule

30 of 33 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 100% of 36 pipeline programs.

Analysis

Trial Status

182

clinical trials

Completed94 · 52%

Unknown status32 · 18%

Recruiting13 · 7%

Terminated13 · 7%

Not yet recruiting12 · 7%

Active, not recruiting7 · 4%

Other11 · 6%

Clinical Trials

Trial Activity

182 trials

A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase IV Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Recruiting·PPharmazz, Inc.·Approved·NCT05955326·160 enrolled

Application of Extended Reality (XR)-Assisted CT-Guided Localization in Extracranial-intracranial (EC-IC) Bypass Surgery

Recruiting·NNational Taiwan University Hospital·N/A·NCT07711457·30 enrolled

Colchicine in Chronic Limb-Threatening Ischemia for Reduction of Complications and Limb Events in Asia

Recruiting·SShin Kong Wu Ho-Su Memorial Hospital·Phase 3·NCT07536373·200 enrolled

Early Vessel Recoil Following Below-the-knee (BTK) Artery Treatment With the Spur Peripheral Retrievable Scaffold System in Specific Patient Populations With Chronic Limb-threatening Ischemia (CLTI) - The DEEPER CHALLENGE Single Center Prospective Study

Recruiting·MMedical University of Graz·N/A·NCT07465627·40 enrolled

Perioperative Nutritional Optimization in Patients With Critical Limb Ischemia

Recruiting·BBoston Medical Center·Phase 1·NCT03529019·30 enrolled

Magnetocardiography in the Identification of Non-Obstructive Myocardial Ischemia of Patients With Acute Chest Pain

Recruiting·QQilu Hospital of Shandong University·N/A·NCT07657546·3,786 enrolled

ORal Antibiotics in Acute Mesenteric Ischemia

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06387147·196 enrolled

Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial

Recruiting·SSupergene, LLC·Phase 3·NCT05372718·170 enrolled

TP03HN106 in Patients With Critical Limb Ischemia

Recruiting·TTalengen Institute of Life Sciences, Shenzhen, P.R. China.·Phase 2·NCT06482892·15 enrolled

Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease

Recruiting·CCell Biopeutics Resources Sdn Bhd·Phase 4·NCT05854615·3 enrolled

Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Critical Limb Ischemia

Recruiting·AAllife Medical Science and Technology Co., Ltd.·Phase 1·NCT06359912·27 enrolled

Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury

Recruiting·TThe Second Hospital of Anhui Medical University·N/A·NCT06947135·166 enrolled

Cerebral Hemodynamic Optimization by Milrinone to Prevent Delayed Cerebral Ischemia

Recruiting·UUniversity Hospital, Toulouse·Phase 2·NCT04282629·234 enrolled

ThromBus Aspiration for Acute Mesenteric Artery Occlusion With Emergent Laparoscopic Surgery: a Multicenter, Prospective Clinical Study

Active, not recruiting·BBeijing Tsinghua Chang Gung Hospital·Preclinical·NCT07741318·76 enrolled

Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study

Active, not recruiting·CCardiovascular and Interventional Radiological Society of Europe·N/A·NCT06149650·400 enrolled

Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)